Samsung Biologics Internalizes MCB and Vector Construction, Strengthening CDO Competitiveness
Direct Execution of Core Cell Line Development Processes Expands End-to-End Services
9-Month Timeline from Vector Construction to IND Submission
Enhanced Data Consistency and IP Protection to Attract New Clients
Samsung Biologics has internalized key processes in the early stages of cell line development, thereby expanding the scope of its contract development (CDO) business. By bringing processes that were previously outsourced in-house, the company has strengthened its responsiveness throughout the entire development process.
Promotional material announcing the simultaneous launch of MCB production and vector manufacturing services by Samsung Biologics. Samsung Biologics
View original imageOn March 23, Samsung Biologics announced that it has internalized the production of Master Cell Bank (MCB) and vector construction services within its CDO service offerings and held a webinar to commemorate the launch. The webinar, held on March 19, was titled "Accelerating from Vector Construction to IND Submission: Achieving a 9-Month Development Timeline Through Integrated Cell Line Development."
During the webinar, Samsung Biologics emphasized that by internalizing MCB production and vector construction services—previously provided through external partners—it has significantly broadened the choices available to clients. The company presented a timeline that enables the completion of the entire process, from vector construction to Investigational New Drug (IND) submission, within nine months. This is part of its plan to provide optimized end-to-end services tailored to client needs.
MCB production and vector construction are essential processes in the manufacture of antibody drugs. Antibody drugs are based on specific antibodies produced in animal cells, and vectors serve as the key gene delivery tools that introduce the genetic information necessary for antibody production into cells. They also contain various regulatory elements that optimize antibody expression within the cell, making precise vector design crucial to maximize expression efficiency and ensure the production of high-quality biopharmaceuticals.
The MCB production service is a solution that mass-produces master cells of the highest quality, selected from cells into which optimized vectors have been inserted, following Good Manufacturing Practice (GMP) compliance assessments. Under strict GMP guidelines, the service is designed to maximize production efficiency while minimizing quality risks.
Samsung Biologics aims to minimize the transfer of clients' drug candidates and related data to third parties by internalizing MCB production and vector construction services that were previously outsourced. By blocking unnecessary external exposure, this approach not only shortens the development period but also ensures consistency in data management and strengthens the protection of clients' intellectual property (IP).
With the addition of these new in-house services, Samsung Biologics has further strengthened its capabilities to meet diverse client needs, in addition to its existing portfolio of nine CDO-related technology platforms. Currently, Samsung Biologics offers a range of CDO services, including: the developability assessment platform "DEVELOPICK™," the proprietary cell line platform "S-CHOice®," the bispecific antibody platform "S-DUAL™," the transient expression platform for candidate molecules "S-CHOsient™," the analytics-based molecule support platform "S-Glyn™," the high-concentration biopharmaceutical development support platform "S-Tensify™," the afucosylated cell line platform "S-AfuCHO™," the protein charge variant control platform "S-Opticharge™," and the high-concentration formulation drug development platform "S-HiCon™."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Sangmyung, Head of CDO Development at Samsung Biologics, stated, "By internalizing cell line development-related services, we expect to become an even faster and more trusted partner in our clients' drug development efforts. We will continue to develop a broader range of technologies and services to provide tailored solutions for our clients."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.